Did they really say that?
This article was originally published in Clinica
Executive Summary
The quotes tell the story. During the last year, many key players in the industry spoke their minds over issues such as the CE mark, user fees, device reuse and FDA reform. Clinica looks back at some of the most controversial and succinct observations.The CE mark for devices "seems only to mean that the person that plugs it in will not get an electric shock". A remark few in the device industry would agree with but it more than exemplified the debate in Europe over the value of the CE mark which continued throughout 1999. It came from Professor Martin Buxton, director of the health economics research group at London's Brunel University, at a meeting on the UK's new National Institute of Clinical Excellence.
You may also be interested in...
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.